SG10201708886RA - α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER - Google Patents

α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER

Info

Publication number
SG10201708886RA
SG10201708886RA SG10201708886RA SG10201708886RA SG10201708886RA SG 10201708886R A SG10201708886R A SG 10201708886RA SG 10201708886R A SG10201708886R A SG 10201708886RA SG 10201708886R A SG10201708886R A SG 10201708886RA SG 10201708886R A SG10201708886R A SG 10201708886RA
Authority
SG
Singapore
Prior art keywords
methods
tumors
compositions
pga
zinc
Prior art date
Application number
SG10201708886RA
Inventor
Fred Chung Jinhyuk
Original Assignee
Xylonix Ip Holdings Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xylonix Ip Holdings Pte Ltd filed Critical Xylonix Ip Holdings Pte Ltd
Priority to SG10201708886RA priority Critical patent/SG10201708886RA/en
Priority to PCT/SG2018/050544 priority patent/WO2019088919A1/en
Priority to EP18799880.2A priority patent/EP3703708A1/en
Priority to JP2020522999A priority patent/JP7352541B2/en
Priority to US16/760,264 priority patent/US20200254013A1/en
Priority to KR1020207014679A priority patent/KR20200080271A/en
Priority to CN201880084765.4A priority patent/CN111542328A/en
Priority to SG11202003967PA priority patent/SG11202003967PA/en
Publication of SG10201708886RA publication Critical patent/SG10201708886RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a -PGA–ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER The invention relates to pharmaceutical compositions comprising a zinc 2+ salt and a a-polyglutamic acid carrier, and, optionally, an NF-kB inhibitor as a tumor-sensitizing agent, and methods for using such compositions to treat tumors in patients. Methods include administering a liquid dosage form or a solid dosage form of a therapeutically effective amount of a Zn(II) salt and a a-polyglutamic acid carrier to a patient in need thereof. Methods of treating a broad spectrum of human tumors, including tumors with a drug-resistant phenotype, using the disclosed compositions are provided. Tumors that respond to the pharmaceutical compositions disclosed herein include neuroendocrine (neuroblastoma), gastric, uterine, and lung tumors. [Figure 2]
SG10201708886RA 2017-10-30 2017-10-30 α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER SG10201708886RA (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
SG10201708886RA SG10201708886RA (en) 2017-10-30 2017-10-30 α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER
PCT/SG2018/050544 WO2019088919A1 (en) 2017-10-30 2018-10-29 Compositions comprising alpha-polyglutamic acid-zinc for treating cancer
EP18799880.2A EP3703708A1 (en) 2017-10-30 2018-10-29 Compositions comprising alpha-polyglutamic acid-zinc for treating cancer
JP2020522999A JP7352541B2 (en) 2017-10-30 2018-10-29 Compositions containing alpha-polyglutamic acid-zinc for treating cancer
US16/760,264 US20200254013A1 (en) 2017-10-30 2018-10-29 Compositions comprising alpha-polyglutamic acid-zinc for treating cancer
KR1020207014679A KR20200080271A (en) 2017-10-30 2018-10-29 Composition for treating cancer comprising alpha-polyglutamic acid-zinc
CN201880084765.4A CN111542328A (en) 2017-10-30 2018-10-29 Compositions comprising alpha-polyglutamic acid-zinc for the treatment of cancer
SG11202003967PA SG11202003967PA (en) 2017-10-30 2018-10-29 Compositions comprising alpha-polyglutamic acid-zinc for treating cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG10201708886RA SG10201708886RA (en) 2017-10-30 2017-10-30 α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER

Publications (1)

Publication Number Publication Date
SG10201708886RA true SG10201708886RA (en) 2019-05-30

Family

ID=64184154

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201708886RA SG10201708886RA (en) 2017-10-30 2017-10-30 α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER
SG11202003967PA SG11202003967PA (en) 2017-10-30 2018-10-29 Compositions comprising alpha-polyglutamic acid-zinc for treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11202003967PA SG11202003967PA (en) 2017-10-30 2018-10-29 Compositions comprising alpha-polyglutamic acid-zinc for treating cancer

Country Status (7)

Country Link
US (1) US20200254013A1 (en)
EP (1) EP3703708A1 (en)
JP (1) JP7352541B2 (en)
KR (1) KR20200080271A (en)
CN (1) CN111542328A (en)
SG (2) SG10201708886RA (en)
WO (1) WO2019088919A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022197246A1 (en) 2021-03-18 2022-09-22 Xylonix Pte. Ltd Pharmaceutical polymer conjugates
US11944640B2 (en) 2016-11-01 2024-04-02 Xylonix PTE. LTD. Zinc-[gamma]-PGA compositions and methods for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
CA2395191A1 (en) * 1999-12-23 2001-06-28 Tedman Ehlers Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
US20020061599A1 (en) * 1999-12-30 2002-05-23 Elling Christian E. Method of identifying ligands of biological target molecules
AU2003232884A1 (en) * 2002-01-25 2003-09-02 Emory University Solenopsin a, b and analogs as novel angiogenesis inhibitors
BRPI0613796A2 (en) * 2005-06-07 2011-02-15 Univ Yale pharmaceutical compositions and their uses, and methods of treating cancer and other pathological conditions or conditions by the use of clevudine (lfmau) and telbivudine (ldt)
WO2007043606A1 (en) 2005-10-12 2007-04-19 Genolac Bl Corporation Antidiabetic agent comprising anionic polyamino acid-metal complex
CN101674852A (en) * 2007-04-10 2010-03-17 日东电工株式会社 Multi-functional polyglutamate drug carriers
JP2010526917A (en) 2007-05-09 2010-08-05 日東電工株式会社 Polyglutamate complex and polyglutamate-amino acid complex having plural kinds of drugs
AU2008251836A1 (en) * 2007-05-09 2008-11-20 Salutria Pharmaceuticals, Llc Spiro compounds for treatment of inflammatory disorders
US20110117210A1 (en) * 2009-11-17 2011-05-19 Andrey Ugolkov Therapeutic treatment of human cancers using simple salts of zinc
EP2978423A4 (en) 2013-03-28 2016-08-24 Bbs Nanotechnology Ltd Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it
US9636411B2 (en) 2013-04-26 2017-05-02 Nitto Denko Corporation Large scale process for preparing poly (glutamyl-glutamate) conjugates
SG10201609131YA (en) * 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11944640B2 (en) 2016-11-01 2024-04-02 Xylonix PTE. LTD. Zinc-[gamma]-PGA compositions and methods for treating cancer
WO2022197246A1 (en) 2021-03-18 2022-09-22 Xylonix Pte. Ltd Pharmaceutical polymer conjugates

Also Published As

Publication number Publication date
CN111542328A (en) 2020-08-14
US20200254013A1 (en) 2020-08-13
EP3703708A1 (en) 2020-09-09
JP7352541B2 (en) 2023-09-28
WO2019088919A1 (en) 2019-05-09
JP2021501143A (en) 2021-01-14
SG11202003967PA (en) 2020-05-28
KR20200080271A (en) 2020-07-06

Similar Documents

Publication Publication Date Title
MX2022011372A (en) Zinc-î³-pga compositions and methods for treating cancer.
MX2021013830A (en) Ezh2 inhibitors for treating lymphoma.
MX2020008258A (en) Pediatric niraparib formulations and pediatric treatment methods.
PH12014501560A1 (en) Carbamate compounds and of making and using same
MX2019012884A (en) Combination therapy.
MX2021001807A (en) Combination of histone deacetylase inhibitor and protein kinase inhibitor and pharmaceutical use thereof.
MX2019013701A (en) Methods of enhancing drug delivery and effectiveness of therapeutic agents.
MX2021008610A (en) Cancer treatment using combinations of erk and raf inhibitors.
MX2019010601A (en) Combination therapy for treating cancer.
MX2016007351A (en) Combination therapy for treating cancer.
WO2016133903A3 (en) Combination therapy for cancer treatment
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
MX2018007823A (en) Bromodomain and extra-terminal protein inhibitor combination therapy.
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
PH12020500666A1 (en) Pladienolide compounds and their use
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
MX2021007330A (en) Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor.
WO2018027084A3 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
MX2022000430A (en) Administration of sting agonist and checkpoint inhibitors.
WO2015035410A8 (en) Cancer therapy
MX2022014792A (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same.
SG10201708886RA (en) α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor